Soft tissue sarcoma of the extremities. A multimodality diagnostic and therapeutic approach

Cancer Treatment Reviews

Volumn 24, Issue 6, 1998, Pages 373-391

  Ham, S J ^a   Van Der Graaf, W T A ^a   Pras, E ^a   Molenaar, W M ^a   Van Den Berg, E ^b   Hoekstra, H J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GAMMA INTERFERON; IFOSFAMIDE; MELPHALAN; METHOTREXATE; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; ELECTRON BEAM; GENE MUTATION; HUMAN; LIMB PERFUSION; LIMB SALVAGE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RADIATION DOSE; RADIATION EXPOSURE; REVIEW; SEX DIFFERENCE; SOFT TISSUE SARCOMA; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE;

EID: 0032469622     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90001-9     Document Type: Review

References (319)

1. Enzinger FM, Weiss SW. General considerations. In: Enzinger FM, Weiss SW, eds, Soft tissue tumors, third edition. St. Louis: Mosby, 1995; 1-16.
2. Angervall L, Kindblom LG. Principles for pathologicAnatomic Diagnosis and Classification of soft-tissue sarcomas. Clin Orthop 1993; 289: 9-18.
3. Weiss SW. Histopathological typing of soft tissue tumors, second edition. (WHO international histopathological classification of tumors). Berlin: Springer Verlag, 1994.
4. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14: 1679-1689.
5. Parker Gibbs C, Peabody TD, Simon MA. Classification, clinical features, preoperative assessment and staging of soft tissue tumors. Current Orthop 1997; 11: 75-82.
6. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1996. CA Cancer J Clin 1996; 46: 5-27.
7. Chang AE, Sondak VK. Clinical evaluation and treatment of soft tissue tumors. In: Enzinger FM, Weiss SW, eds, Soft tissue tumors, third edition. St. Louis: Mosby, 1995; 17-38.
8. Chang AE, Rosenberg SA, Glatstein EJ, Antman KH. Sarcomas of soft tissues. In: DeVita Jr. VT, Hellman S, Rosenberg SA, eds, Cancer principles & practice of oncology, third edition. Philadelphia: J.B. Lippincott Company, 1989; 1345-1398.
9. Laskin WB, Silverman TA, Enzinger FM. Post-radiation soft tissue sarcomas; an analysis of 53 cases. Cancer 1988; 62: 2330-2340.
10. Davidson T, Westbury G, Harmer CL. Radiation-induced soft-tissue sarcoma. Br J Surg 1986; 73: 308-309.
11. Mark RJ, Poen J, Tran LM, Fu YS, Selch MT, Parker RG. Postirradiation sarcoma: a single institution study and a review of the literature. Cancer 1994; 73: 2653-2662.
12. Zahm SH, Fraumeni JF, Jr. The epidemiology of soft tissue sarcoma. Seminars Oncology 1997; 24: 504-514.
13. Zahm SH, Tucker MA, Fraumeni JF, Jr. Soft tissue sarcomas. In: Schottenfeld D, Fraumeni JF, Jr., eds, Cancer epidemiology and prevention, second edition. New York: Oxford University Press, 1996; 984-999.
14. Hardell L, Eriksson M. The association between soft tissue sarcomas and exposure to phenoxyacetic acids: A new case-referent study. Cancer 1988; 62: 652-656.
15. Kang H, Enzinger FM, Breslin P, et al. Soft tissue sarcoma and military service in Vietnam; a case-control study. J Natl Cancer Inst 1987; 79: 693-699.
16. Fingerhut MA, Halperin WE, Marlow DA, et al. Cancer mortality in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. N Engl J Med 1991; 324: 212-218.
17. Saracci R, Kogevinas M, Bertazzi PA, et al. Cancer mortality in workers exposed to chlorophenoxy herbicides and chlorophenols. Lancet 1991; 338: 1027-1032.
18. Erikkson M, Hardell L, Adami HO. Exposure to dioxins as a risk factor for soft tissue sarcoma: a population-based case-control study. J Natl Cancer Inst 1990; 82: 486-490.
19. McClay EF. Epidemiology of bone and soft tissue sarcomas. Semin Oncol 1989; 16: 264-272.
20. Hibshoosh H, Lattes R. Immunohistochemical and molecular genetic approaches to soft tissue tumor diagnosis: a primer. Semin Oncol 1997; 5: 515-525.
21. Fletcher JA. Cytogenetic analysis of soft tissue tumors. In: Enzinger FM, Weiss SW, eds, Soft tissue tumors, third edition. St. Louis: Mosby, 1995; 105-118.
22. Sreekantaiah C, Ladanyi M, Rodriquez E, et al. Review chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classification, and molecular mechanisms. Am J Pathol 1994; 144: 1121-1134.
23. Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 1986; 314: 1010-1015.
24. Cance WG, Brennan MF, Dudas ME, Huang C-M, Cordon-Cardo C. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 1990; 323: 1457-1462.
25. Knight JC. The molecular genetics of soft tissue sarcoma. Eur J Cancer 1990; 26: 511-513.
26. Rustgi AK. Hereditary gastrointestinal polyposis and non-polyposis syndromes. N Engl J Med 1994; 331: 1694-1702.
27. Meltzer PS. Molecular biology of soft tissue tumors. In: Enzinger FM, Weiss SW, eds, Soft tissue tumors, third edition. St. Louis: Mosby, 1995; 89-104.
28. Leach FS, Tokino T, Meltzer P, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231-2234.
29. Hung J, Anderson R. P53: functions, mutations and sarcomas. Acta Orthop Scand 1997; 68 [Suppl 273]: 68-73.
30. Yoo J, Lee HK, Kang CS, Park WS, Lee JY, Shim SI. p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch Pathol Lab Med 1997; 121: 395-399.
31. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994; 69:409-416.
32. Wunder JS, Czitrom AA, Kandel R, Andrulis IL. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft tissue sarcomas. J Natl Cancer Inst 1991; 83: 194-200.
33. Karpeh MS, Brennan MF, Cance WG, et al. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Surg 1995; 72: 986-991.
34. Toguchida J, Yamaguchi T, Ritchie B, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992; 52: 6194-6199.
35. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54: 794-799.
36. Latres E, Drobnjak M, Pollack D, et al. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 1994; 145: 345-355.
37. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
38. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83.
39. Xiao Z-X, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375: 694-698.
40. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 1993; 53: 5535-5541.
41. Smith SH, Weiss SW, Jankowski SA, Coccia MA, Meltzer PS. SAS amplification in soft tissue sarcomas. Cancer Res 1992; 52: 3746-3749.
42. Roberts WM, Douglass EC, Peiper SC, Houghton PJ, Look AT. Amplification of the gli gene in childhood sarcomas. Cancer Res 1989; 49: 5407-5413.
43. Srivastava S, Zou ZQ, Pirollo K, Blattner WA, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-749.
44. Malkin D, Li FP, Strong LC, et al. Germ line mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
45. Brugières L, Gardes M, Moutou C, et al. Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. Cancer Res 1993; 53: 452-455.
46. Varley JM, mcGown G, Thorncroft M, et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 1997; 57: 3245-3252.
47. Li FP, Fraumeni JF, Jr., Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48: 5358-5362.
48. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF, Jr., Li FP. Follow-up study of twenty-four families with Li-Fraumeni Syndrome. Cancer Res 1991; 51: 6094-6097.
49. Li FP, Fraumeni JF, Jr. Soft tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 1969; 71: 747-752.
50. Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992; 326: 1301-1308.
51. Malkin D, Jolly KW, Barbier N, et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1992; 326: 1309-1315.
52. Petasnick JP, Turner DA, Charters JR, Gitelis S, Zacharias CE. Soft tissue masses of the locomotor system: comparison of MR imaging with CT. Radiology 1986; 160: 125-133.
53. Tehranzadeh J, Mnaymneh W, Ghavam C, Morillo G, Murphy B. Comparison of CT and MR imaging in musculoskeletal neoplasm. J Comp Assist Tomogr 1989; 13: 466-472.
54. Hogeboom WR, Hoekstra HJ, Mooyaart EL, Freling NJ, Schraffordt Koops H. MRI and CT in the preoperative evaluation of soft-tissue tumors. Arch Orthop Trauma Surg 1991; 110: 162-164.
55. Chang AE, Matury YL, Dwyer AJ, et al. Magnetic resonance imaging versus computed tomography in the evaluation of soft tissue tumors of the extremities. Ann Surg 1987; 205: 340-348.
56. Gilbert TJ, Jr., Thompson RC, Jr. Imaging of soft tissue tumors. Current Orthop 1997; 11: 83-97.
57. Peabody TD, Simon MA. Principles of staging of soft-tissue sarcomas. Clin Orthop 1993; 289: 19-31.
58. Reuther G, Mutschler W. Detection of local recurrence disease in musculoskeletal tumors: Magnetic resonance imaging versus computed tomography. Skeletal Radiol 1990; 19: 85-90.
59. Vanel D, Shapeero LG, De Baere T, et al. MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: results of 511 examinations. Radiology 1994; 190: 263-268.
60. Nieweg OE, Pruim J, Ginkel RJ van, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37: 257-261.
61. Strauss LG, Conti PS. The applications of PET in clinical biology. J Nucl Med 1991; 32: 623-648.
62. 18F] FDG. J Comput Assist Tomogr 1990; 14: 960-962.
63. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with fluorine-18-fluoro-2-deoxy-D-glucose. Radiology 1992; 182: 185-194.
64. 18F] fluorodeoxyglucose. Ann Surg Oncol 1997; 4: 57-63.
65. Ham SJ, Pras E, Hoekstra HJ. Buttockectomy as a limbsaving procedure for locally advanced soft tissue sarcoma of the buttock region. Eur J Surg Oncol 1998; 24: 184-187.
66. Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. J Bone Joint Surg 1996; 78A: 656-663.
67. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft tissue tumors. J Bone Joint Surg 1982; 64A: 1121-1127.
68. Simon MA, Biermann JS. Biopsy of bone and soft-tissue lesions. J Bone Joint Surg 1993; 75A: 616-621.
69. Yasko AW, Reece GP, Gillis TA, Pollock RE. Limb-salvage strategies to optimize quality of life: the M.D. Anderson Cancer Center experience. Ca Cancer J Clin 1997; 47: 226-238.
70. Rydholm A, Gustafson P, Rööser B, et al. Limb-sparing surgery without radiotherapy based on anatomic location of soft tissue sarcoma. J Clin Oncol 1991; 9: 1757-1765.
71. Berlin Ö, Stener B, Angervall L, Kindblom LG, Markhede G, Oden A. Surgery for soft tissue sarcoma in the extremities. A multivariate analysis of the 6-26-year prognosis in 137 patients. Acta Orthop Scand 1990; 61: 475-486.
72. Plaat BEC, Muntinghe FLH, Molenaar WM, et al. Clinical out-come of patients with previously untreated soft tissue sarcomas in relation to tumor grade, DNA ploidy and karyotype. Int J Cancer 1997; 74: 396-402.
73. Berg E van den, Molenaar WM, Hoekstra HJ, Kamps WA, Jong B de. DNA ploidy and karyotype in recurrent and metastatic soft tissue sarcomas. Modern Pathol 1992; 5: 505-514.
74. Cheng EY, Thompson RC, Jr. Soft-tissue sarcomas, in: Pritchard DJ, ed, Instructional course lectures, volume 45. Rosemont: American Academy of Orthopaedic Surgeons, 1996; 461-471.
75. Kreicbergs A. DNA cytometry of musculoskeletal tumors. A review. Acta Orthop Scand 1990; 61: 282-297.
76. Berg E van den, Oven MW van, Jong B de, et al. Comparison of cytogenetic abnormalities and deoxyribonucleic acid ploidy of benign, borderline malignant, and different grades of malignant soft tissue tumors. Lab Invest 1994; 70: 307-313.
77. Alvegård TA, Berg NO, Baldetorp B, et al. Cellular DNA content and prognosis of high-grade soft tissue sarcoma: The Scandinavian sarcoma group experience. J Clin Oncol 1990; 8: 538-547.
78. el-Naggar AK, Ayala AG, Abdul-Karim FW, et al. Synovial sarcoma. A DNA flow cytometric study. Cancer 1990; 65: 2295-2300.
79. Gustafson P, Rydholm A, Willen A, Baldetorp B, Ferno M, Akerman M. Liposarcoma: a population-based epidemiologic and prognostic study of features of 43 patients, including tumor DNA content. Int J Cancer 1993; 55: 541-546.
80. Molenaar WM, Jong B de, Buist J, et al. Chromosomal analysis and the classification of soft tissue sarcomas. Lab Invest 1989; 60: 266-274.
81. Fletcher JA, Kozakewich HP, Hoffer FA, et al. Diagnostic relevance of clonal cytogenic aberrations in malignant soft tissue tumors. N Engl J Med 1991; 324:436-442.
82. Carbone A, Gloghini A, Volpe R. The value of immunohistochemistry in soft tissue sarcomas. Ann Oncol 1992; 3 [Suppl 2]: S51-S54.
83. Heslin M, Lewis J, Woodruff J, Brennan M. Core needle biopsy for diagnosis of extremity soft tissue sarcomas. Ann Surg Oncol 1997; 4: 425-431.
84. Barth RJ, Jr., Merino MJ, Solomon D, Yang JC, Baker AR. A prospective study of the value of core needle biopsy and fine needle aspiration in the diagnosis of soft tissue masses. Surgery 1992; 112: 536-543.
85. Ball AB, Fisher C, Pittam M, Watkins RM, Westbury G. Diagnosis of soft tissue tumors by Tru-cut biopsy. Br J Surg 1990; 77: 756-758.
86. Molenaar WM, Berg E van den, Dolfin AC, Zorgdrager H, Hoekstra HJ. Cytogenics of fine needle aspiration biopsies of sarcomas. Cancer Gen Cytogen 1995; 84: 27-31.
87. Lawrence W, Jr., Donegan WI, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 1987; 205: 349-359.
88. Russell WO, Cohen J, Enzinger F, et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer 1977; 40: 1562-1570.
89. Beahrs OH, Henson DE, Hutter RVP, et al., eds, Manual for staging of Cancer, fourth edition. Philadelphia: J.B. Lippincott, 1992.
90. Soft tissue sarcomas. In: Fleming ID, Cooper JS, Henson DE, et al., eds, American Joint Committee on Cancer (AJCC). (AJCC) cancer staging manual, fifth edition. Philadelphia: J.B. Lippincott, 1997; 149-156.
91. Enneking WF, Spanier SS, Goodman MA. A System for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980; 153: 106-120.
92. Hajdu SI. Pathology of soft tissue tumors. Philadelphia: Lea & Feibiger, 1979; 35-47.
93. Coindre JM, Terrier P, Bui N, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma: A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996; 14: 869-877.
94. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand 1994; 65[Suppl 259]: 1-31.
95. Shiu MH, Castro EB, Hajdu SI, Fortner JC. Surgical treatment of 297 soft tissue sarcomas of the lower extremity. Ann Surg 1975; 182: 597-602.
96. Eilber FR, Eckardt J. Surgical management of soft tissue sarcomas. Semin Oncol 1997; 24: 526-533.
97. Karakousis CP, Emrich LJ, Rao U, Krishnamsetty RM. Feasibility of limb salvage and survival in soft tissue sarcomas. Cancer 1986; 57: 484-491.
98. Abbas JS, Holyoko ED, Moore R, Karakousis CP. The surgical treatment and outcome of soft-tissue sarcoma. Arch Surg 1981; 116: 765-769.
99. Cadman NL, Soule EH, Kelly TJ. Synovial sarcoma: An analysis of 134 tumors. Cancer 1965; 18: 613-627.
100. Simon MA, Enneking WF. The management of soft-tissue sarcomas of the extremities. J Bone Joint Surg 1976; 58A: 317-327.
101. Eilber FR, Mirra JJ, Grant TT, Weisenburger T, Morton DL. Is amputation necessary for sarcomas? A seven-year experience with limb-salvage. Ann Surg 1980; 192:431-437.
102. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982; 196: 305-315.
103. Rydholm A, Rööser B. Surgical margins for soft tissue sarcoma. J Bone Joint Surg 1987; 69A: 1074-1078.
104. Cantin J, McNeer GP, Chu FC, Booker RJ. The problem of local recurrence after treatment of soft tissue sarcoma. Ann Surg 1968; 168: 47-53.
105. Markhede G, Angervall L, Stener B. A multivariate analysis of the prognosis after surgical treatment of malignant soft-tissue tumors. Cancer 1982; 49: 1721-1733.
106. Gerner RE, Moore GE, Pickren JW. Soft tissue sarcomas. Ann Surg 1975; 181: 803-808.
107. Casper ES, Gaynor JJ, Harrison LB, Panicek DM, Hajdu SI, Brennan MF. Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma. Cancer 1994; 73: 1644-1651.
108. Kraybill WG, Emami B, Lyss AP. Management of soft tissue sarcomas of the extremities. Surgery 1991; 109: 233-235.
109. Brennan MF, Hilaris BS, Shiu MH, et al. Local recurrence in adult soft tissue sarcoma: A randomized trial of brachytherapy. Arch Surg 1987; 122: 1289-1293.
110. Pisters PWT, Harrison LB, Leung DHY, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996; 14: 859-868.
111. Morton DL, Eilber FR, Townsend CM, Grant TT, Mirra J, Weisenburger TH. Limb salvage from a multidisciplinary treatment approach for skeletal and soft tissue sarcomas of the extremity. Ann Surg 1976; 184: 268-278.
112. Eilber FR, Giuliano AE, Huth JF, Weisenburger T, Eckardt FR. Intravenous (IV) versus intraarterial (IA) adriamycin, 2800 cGy radiation and surgical excision for extremity soft tissue sarcomas; a randomized prospective trial. Proc Am Soc Clin Oncol 1990; 9: 309 (Abstr. 1194).
113. Eilber F, Eckardt J, Rosen G, Forscher C, Selch M, Fu YS. Preoperative neoadjuvant chemotherapy and radiation for high grade extremity sarcomas: UCLA experience. Anti-Cancer Treatment; Sixth International Congres, p 86, Paris, February 1996.
114. Eilber F, Giuliano A, Huth J, Mirra J, Rosen G, Morton D. Neoadjuvant chemotherapy, radiation, and limited surgery for high grade soft tissue sarcoma of the extremity. Dev Oncol 1988; 55: 115-122.
115. Eilber F, Eckardt J, Rosen G, Forscher C, Selch M, Fu YS. Improved complete response rate with neoadjuvant chemotherapy and radiation for high grade extremity soft tis-sue sarcoma. Proc Am Soc Clin Oncol 1994; 13:473 (Abstr. 1645).
116. Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992; 215: 269-275.
117. Meterissian S, Reilly J, Jr., Murphy A, Romsdahl MM, Pollock RE. Soft tissue sarcomas of the shoulder girdle: factors influencing local recurrence, distant metastasis and survival. Ann Surg Oncol 1995; 2: 530-536.
118. Alho A, Alvegård TS, Berlin O, et al. Surgical margin in soft tissue sarcoma. Acta Orthop Scand 1989; 60: 687-692.
119. Giuliano AE, Eilber FR. The rationale for planned reoperation after unplanned total excision of soft-tissue sarcomas. J Clin Oncol 1985; 3: 1344-1348.
120. O'Connor MI. Surgical management of malignant soft tissue tumors. In: Simon MA, Springfield D, eds, Surgery for bone and soft tissue tumors. Philadelphia: Lippincott-Raven Publishers, 1998; 555-565.
121. Petty PM, Terkonda SP, Shives TC. Reconstruction of soft-tissue defects. In: Simon MA, Springfield D, eds, Surgery for bone and soft tissue tumors. Philadelphia: Lippincott-Raven Publishers, Philadelphia, 1998; 585-596.
122. Krag DN, Klein H, Schneider PD, Goodnight JE, Jr. Composite tissue transfer in limb-salvage surgery. Arch Surg 1991; 126: 639-641.
123. Barwick WJ, Goldberg JA, Scully SP, Harrelson JM. Vascularized tissue transfer for closure of irradiated wounds after soft tissue sarcoma resection. Ann Surg 1992; 216: 591-595.
124. Reece GP, Schusterman MA, Pollock RE, et al. Immediate versus delayed free-tissue transfer salvage of the lower extremity in soft tissue sarcoma patients. Ann Surg Oncol 1994; 1: 11-17.
125. Ham SJ, Schraffordt Koops H, Veth RPH, van Horn JR, Eisma WH, Hoekstra HJ. External and internal hemipelvectomy for sarcomas of the pelvic girdle: consequences of limb-salvage treatment. Eur J Surg Oncol 1997; 23: 540-546.
126. Lee GW, MacKinnon SE, Brandt K, Bell RS. A technique for nerve reconstruction following resection of soft tissue sarcoma. J Reconstr Microsurg 1993; 9: 139-144.
127. Breidenbach WC, Terzis JK. Vascularized nerve grafts: an experimental and clinical review. Ann Plast Surg 1987; 18: 137-146.
128. Nambissan RN, Karakousis CP. Vascular reconstruction for limb salvage in soft tissue sarcomas. Surgery 1987; 101: 668-677.
129. Steed DL, Peitzman AB, Webster MW, Jr, Ramasastry SS, Goodman MA. Limb sparing operations for sarcomas of the extremities involving critical arterial circulation. Surg Gynecol Obstet 1987; 164: 493-498.
130. Karakousis L, Karnpaliotis C, Driscoll B. Major vessel resection during limb-preserving surgery for soft tissue sarcoma. World J Surg 1996; 20: 345-350
131. Sadoski C, Suit HD, Rosenberg A, Mankin H, Efird J. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol 1993; 52: 223-230.
132. Karakousis CP, Proimakis C, Walsh DL. Primary soft tissue sarcoma of the extremities in adults. Br J Surg 1995; 82: 1208-1212.
133. Slater A, A'Hern R, Fisher C, Mott AF, Fallowfield ME, Westbury G. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 1990; 65: 1119-1129.
134. Karakousis C, Pevimakis C, Rao U, et al. Local recurrence and survival in soft tissue sarcoma. Ann Surg Oncol 1996; 3: 255-260.
135. Prewitt T, Alexander H, Sindelar W. Hemipelvectomy for soft tissue sarcoma: clinical results in fifty-three patients. Surg Oncol 1995; 4: 261-269.
136. Ham SJ, Hoekstra HJ, Schraffordt Koops H, Eisma WH, Oldhoff J. The interscapulothoracic amputation in the treatment of malignant diseases of the upper extremity with a review of the literature. Eur J Surg Oncol 1993; 19: 543-548.
137. Sugarbaker PH. Forequarter amputation. In: Sugarbaker PH, Malawer MM, eds, Musculoskeletal surgery for cancer. Principles and techniques. New York: Thieme Medical Publishers, 1991; 306-316.
138. Malawer MM, Sugarbaker PH. Internal hemipelvectomy. In: Sugarbaker PH, Malawer MM, eds., Musculoskeletal surgery for cancer. Principles and techniques. New York: Thieme Medical Publishers, 1991;...
139. Ham SJ, Hoekstra HJ, Eisma WH, Schraffordt Koops H, Oldhoff J. The Tikhoff-Linberg procedure in the treatment of sarcomas of the shoulder girdle. J Surg Oncol 1993; 53: 71-77.
140. Marcove RC, Lewis MM, Huvos AG. En bloc upper interscapulothoracic resection. The Tikhoff-Linberg procedure. Clin Orthop 1977; 124: 219-228.
141. Malawer MM, Sugarbaker PH. Shoulder girdle resections: the Tikhoff-Linberg procedure and its modifications. In: Sugarbaker PH, Malawer MM, eds,. Musculoskeletal surgery for cancer. Principles and techniques. New York: Thieme Medical Publishers, 1991; 346-360.
142. Dell PC. Hand. In: Simon MA, Springfield D, eds, Surgery for bone and soft tissue tumors. Philadelphia: Lippincott-Raven Publishers, 1998; 405-420.
143. Harrelson JM. Foot. In: Simon MA, Springfield D, eds, Surgery for bone and soft tissue tumors. Philadelphia: Lippincott-Raven Publishers, 1998; 421-434.
144. Kinsella TJ. Limited surgery and radiation therapy for sarcomas of the hand and foot. Int J Radiat Oncol Biol Phys 1986; 12: 2045-2046.
145. Talbert ML, Zagars GK, Sherman NE, Romsdahl MV. Conservative surgery and radiation therapy for soft tissue sarcoma of the wrist, hand, ankle, and foot. Cancer 1990; 66: 2482-2491.
146. Okunieff P, Suit HD, Proppe KH. Extremity preservation by combined modality treatment of sarcoma of hand and wrist. Int J Radiat Oncol Biol Phys 1986; 12: 1923-1929.
147. Selch MT, Kopald KH, Ferreiro GA, Mirra JM, Parker RG, Eilber FR. Limb salvage therapy for soft tissue sarcomas of the foot. Int J Radiat Oncol Biol Phys 1990; 19: 41-48.
148. Brien EW, Terek RM, Geer RJ, Caldwell G, Brennan MF, Healey JH. Treatment of soft-tissue sarcomas of the hand. J Bone Joint Surg 1995; 77 A: 564-571.
149. Owens JC, Shiu MH, Smith R, Hajdu SI. Soft tissue sarcomas of the hand and foot. Cancer 1985; 55: 2010-2018.
150. Ham SJ, Hoekstra HJ, Eisma WH, Oldhoff J, Schraffordt Koops H. The feasibility of hind foot amputation in selected sarcomas of the foot. J Surg Oncol 1992; 50: 37-42.
151. Geer RJ, Woodruff J, Casper ES, Brennan MF. Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg 1992; 127: 1285-1289.
152. Spiro IJ, Gebhardt MC, Jennings LC, Mankin HJ, Harmon DC, Suit HD. Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Oncol 1997; 24: 540-546.
153. Ngan SY. Radiotherapy in soft tissue sarcoma of the extremities. Acta Orthop Scand 1997; 68 [Suppl 273]: 112-116.
154. Potter D, Kinsella T, Glatstein E, et al. High-grade soft tissue sarcomas of the extremities. Cancer 1986; 58: 190-205.
155. Lindberg R. Treatment of localized soft tissue sarcomas in adults at MD Anderson Hospital and Tumor institute (1960-1981). Cancer Treat Symp 1985; 3: 59-65.
156. Suit HD, Markin HJ, Wood WC, Proppe KH. Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. Cancer 1985; 55: 2659-2667.
157. Barkley T, Martin R, Romsdahl M, Pindberg R, Zagars GK. Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection. Int J Radiat Oncol Biol Phys 1988; 14: 693-699.
158. Suit HD. The George Edelstyn memorial lecture: Radiation in the management of malignant soft tissue tumours. Clin Oncol 1989; 1: 5-10.
159. Suit HD, Mankin HJ, Wood WC, et al. Treatment of the patient with stage MO soft tissue sarcoma. J Clin Oncol 1988; 6: 854-862.
160. Lindberg RD, Martin RG, Romsdahl MM, Barkley HT. Conservative surgery and postoperative radiotherapy in 300 adults with soft tissue sarcomas. Cancer 1981; 47: 2391-2397.
161. Suit HD, Russell WO, Martin RG. Sarcoma of soft tissue: Clinical and histopathologic parameters and response to treatment. Cancer 1975; 35: 1478-1483.
162. Avizonis VN, Sause WT, Menlove RL. Utility of surgical margins in the radiotherapeutic management of soft tissue sarcomas. J Surg Oncol 1990; 45: 85-90.
163. Herbert SH, Corn BW, Solin LJ, et al. Limb-preserving treat-ment for soft tissue sarcomas of the extremities. The significance of surgical margins. Cancer 1993; 72: 1230-1238.
164. Brant TS, Parsons JT, Marcus RB, et al. Preoperative irradiation for soft tissue sarcomas of the trunk and extremities in adults, Int J Radiat Oncol Biol Phys 1990; 19: 899-906.
165. Fein DA, Lee WR, Lanciano RM, et al. Management of extremity soft tissue sarcomas with limb-sparing surgery and postoperative irradiation: do total dose overall treatment time and the surgery-radiotherapy interval impact on local control? Int J Radiat Oncol Biol Phys 1995; 32: 969-976.
166. Mundt AJ, Awan A, Sibley GS, et al. Conservative surgery and adjuvant radiation therapy in the management of adult soft tissue sarcoma of the extremities: clinical and radiobiological results, Int J Radiat Oncol Biol Phys 1995; 32: 977-985.
167. Leibel SA, Transbaugh RF, Wara WM, Beckstead JH, Bovill EG, Phillips TL. Soft tissue sarcomas of the extremities. Survival patterns of failure with conservative surgery and post-operative irradiation compared to surgery alone. Cancer 1982; 50: 1076-1083.
168. Pao WJ, Pilepich MV. Postoperative radiotherapy in the treatment of extremity soft tissue sarcomas, Int J Radiat Oncol Biol Phys 1990; 19: 907-911.
169. Singer S, Corson JM, Gonin R, Labow B, Eberlein TJ. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 1994; 219: 165-173.
170. Tanabe KK, Pollock RE, Ellis LM, Murphy A, Sherman N, Romsdahl MM. Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas. Cancer 1994; 73: 1652-1659.
171. LeVay J, O'Sullivan B, Catton C, et al. Outcome and prognostic factors in soft tissue sarcoma in the adult, Int J Radiat Oncol Biol Phys 1993; 27: 1091-1099.
172. Stinson SF, DeLaney TF, Greenberg J, et al. Acute and long-term effects on limbfunction of combined modality limb sparing therapy for extremity soft tissue sarcoma, Int J Radiat Oncol Biol Phys 1991; 21: 1493-1499.
173. Bujko K, Suit HD, Springfield DS, Convery K. Wound healing after preoperative radiation for sarcoma of soft tissues. Surg Gynecol Obstet 1993; 176: 124-134.
174. Arbeit J, Hilaris B, Brennan M. Wound complications in the multi-modality treatment of extremity and superficial truncal sarcomas. J Clin Oncol 1987; 5: 480-488.
175. Wiklund TA, Alvegård TA, Mouridsen HT, Rydholm A, Blomqvist CP. Marginal surgery and postoperative radiotherapy in soft tissue sarcomas. The Scandinavian Sarcoma Group experience. Eur J Cancer 1993; 29A: 306-309.
176. Robinson MH, Ball AB, Schofield J, Fisher C, Harmer CL, Thomas JM. Preoperative radiotherapy for initially inoperable extremity soft tissue sarcomas. Clin Oncol 1992; 4: 36-43.
177. Hoekstra HJ, Sindelar WF, Kinsella TJ, Oldhoff J. History, preliminary results, complications and future prospects of intraoperative radiotherapy. J Surg Oncol 1987; 36: 175-182.
178. Nori D, Shupak K, Shiu MH, Brennan MF. Role of brachytherapy in recurrent extremity sarcoma in patients treated with prior surgery and irradiation. Int J Radiat Oncol Biol Phys 1991; 20: 1229-1233.
179. Zelefsky MJ, Nori D, Shiu MH, Brennan MF. Limb salvage in soft tissue sarcomas involving neurovascular structures using combined surgical resection and brachytharapy. Int J Radiat Oncol Biol Phys 1990; 19: 913-918.
180. Brennan MF, Casper ES, Harrison LB, Shiu MH, Gaynor J, Hajdu SI. The role of multimodality therapy in soft-tissue sarcoma. Ann Surg 1991; 214: 328-338.
181. Tepper JE, Suit HD. Radiation therapy alone for sarcoma of soft tissue. Cancer 1985; 56: 475-479.
182. Slater JD, McNeese MD, Peters LJ. Radiation therapy for unresectable soft tissue sarcomas, Int J Radiat Oncol Biol Phys. 1986; 12: 1729-1734.
183. Devereaux DF, Wilson RE, Corson JM, Antman KH, Greenberger JS. Surgical treatment of low grade soft tissue sarcomas. Am J Surg 1982; 143: 490-494.
184. Hoekstra HJ, Schraffordt Koops H, Molenaar WM, Oldhoff J. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 1987; 60: 1703-1707.
185. McBride CM. Sarcomas of the limbs: Result of adjuvant chemotherapy using isolation perfusion. Arch Surg 1974; 109: 304-308.
186. Lehti PM, Moseley HS, Janoff K, Stevens K, Fletcher WS. Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 1986; 162: 149-152.
187. Klaase JM, Kroon BBR, Benckhuysen C, Geel AN van, AlbusLutter Ch E, Wieberdink J. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989; 64: 616-621.
188. Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994; 73: 2140-2146.
189. DiFilippo F, Calabro AM, Cavallari A, et al. The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcomas of the extremities. World J Surg 1988; 12: 332-339.
190. Ginkel RJ van, Schraffordt Koops H, Vries EGE de, Molenaar WM, Uges DRA, Hoekstra HJ. Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone. Eur J Surg Oncol 1996; 22: 528-531.
191. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolated perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
192. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft-tissue extremity sarcomas. The cumulative multicenter european experience. Ann Surg 1996; 224: 756-765.
193. Eggermont AMM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high dose tumor necrosis factor-α in combination with interferon-γ and melphalan for irresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol 1996; 14: 2653-2665.
194. Gutman M, Inbar M, Lev-Shlush D, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced
195. Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T, Thomas TM. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993; 80: 995-997.
196. Olieman AFT, Pras E, Ginkel RJ van, Molenaar WM. Schraffordt Koops H, Hoekstra HJ. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-α and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma, Int J Radiat Oncol Biol Phys 1998; 40: 807-814.
197. Renard N, Lienard D, Lespagnard L, Eggermont AMM, Heimann R, Lejeune FJ. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha (rTNFα). Int J Cancer 1994; 57: 656-663.
198. Olieman AFT, Ginkel RJ van, Hoekstra HJ, Mooyaart EL, Molenaar WM, Schraffordt Koops H. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997; 4: 64-69.
199. Zwaveling JH, Maring JK, Clarke FL, et al. High plasma tumor necrosis factor (TNF)-α concentrations and a sepsislike syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinat TNF-α, interferon-γ, and melphalan. Crit Care Med 1996; 24: 765-770.
200. Sorkin P, Abu-Abid S, Lev D, et al. Systemic leakage and side effects of tumor necrosis factor administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg 1995; 130: 1079-1084.
201. 31P Magnetic resonance spectroscopy as indicator for clinical response in human extremity sarcomas treated by single dose TNF-a and melphalan isolated limb perfusion. NMR Biomed 1995; 8: 215-224.
202. Nieweg OE, Pruim J, Hoekstra HJ, et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft-tissue sarcoma. J Nucl Med 1994; 35: 90-92.
203. Ginkel RJ van, Hoekstra HJ, Pruim J, et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft tissue sarcoma. J Nucl Med 1996; 37: 984-990.
204. 11C]tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft tissue sarcoma and skin cancer. Submitted
205. Yasko AW, Lane JM. Chemotherapy for bone and soft-tissue sarcomas of the extremities. J Bone Joint Surg 1991; 73A: 1263-1271.
206. Alvegård TA, Sigurdsson H, Mouridsen H, et al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: A randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol 1989; 7: 1504-1513.
207. Gherlinzoni F, Bacci G, Picci P, et al. A randomized trial for the treatment of high grade soft tissue sarcomas of the extremities: Preliminary observations. J Clin Oncol 1986; 4: 552-558.
208. Gherlinzoni F, Picci P, Bacci G, et al. Late results of a randomized trial for the treatment of soft tissue sarcomas of the extremities in adult patients. Proc Am Soc Clin Oncol 1993; 12: 1633 (Abstr.).
209. Eilber FR, Giuliano AE, Huth JF, Morton DL. A randomized prospective trial using postoperative chemotherapy (adriamycin) in high grade extremity soft-tissue sarcoma. Am J Clin Oncol 1988; 11: 39-45.
210. Antman K, Ryan L, Borden E, et al. Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10 year result and review of the literature. In: Salmon S.E., ed, Adjuvant therapy of cancer, sixth edition. Philadelphia: W.B. Saunders, 1990; 529-543.
211. Chang A, Kinsella T, Glatstein E, et al. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol 1988; 6: 1491-1500.
212. Edmonson JH, Fleming TR, Ivans JC, et al. Randomized study of systemic chemotherapy following complete excision of nonosseouos sarcomas. J Clin Oncol 1984; 2: 1390-1396.
213. Bramwell V, Rouëssé J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma reduced local recurrence but no improvement in survival: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994; 12: 1137-1149.
214. Ravaud A, Bui N, Coindre J, et al. Adjuvant chemotherapy with CYVADIC in high risk soft tissue sarcoma: A randomized prospective trial. In: Salmon S.E., ed, Adjuvant therapy of cancer, sixth edition. Philadelphia: W.B. Saunders, 1990; 556-566.
215. Benjamin RS, Terjanian TO, Genoglio CJ, et al. The importance of combination chemotherapy for adjuvant treatment of high risk patients with soft tissue sarcomas of the extremities. In: Salmon S.E., ed, Adjuvant therapy of cancer, fifth edition. Orlando: Grune and Stratton, 1987; 735-744.
216. Mertens WC, Bramwell VHC. Adjuvant chemotherapy in the treatment of soft-tissue sarcoma. Clin Orthop 1993; 289:81-93.
217. Phillips KA, Toner GC. Chemotherapy for soft tissue sarcomas. Indications and advances. Acta Orthop Scand 1997; 68 [Suppl 273]: 133-138.
218. Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MK. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomized clinical trials. Br J Cancer 1995; 72:469-475.
219. Sarcoma meta-analysis collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcomas of adults: meta-analysis of individual data. Lancet 1997; 350: 1647-1654.
220. Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol 1997; 24: 556-560.
221. Serpell JW, Ball ABS, Robinson MH, Fryatt I, Fisher C, Thomas JM. Factors influencing local recurrence and survival in patients with soft tissue sarcoma of the upper limb. Br J Surg 1991; 78: 1368-1372.
222. Stotter AT, A'Hern RP, Fisher C, Mott AF, Fallowfield ME, Westbury G. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 1990; 65: 1119-1129.
223. Gustafson P, Rööser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 1991; 67: 2083-2086.
224. Rydholm A, Gustafson P, Rööser B, Willen H, Berg NO. Subcutaneous sarcoma. A population-based study of 129 patients. J Bone Joint Surg 1991; 73B: 662-667.
225. Collin C, Godbold J, Hajdu S, Brennan MF. Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 1987; 5: 601-612.
226. Gustafson P, Rydholm A. Selection bias in treatment of soft-tissue sarcoma. J Bone Joint Surg 1992; 74B: 501-503.
227. Rydholm A. Prognostic factors in soft tissue sarcoma. Acta Orthop Scand 1997; 68 [Suppl 273]: 148-155.
228. Brooks AD, Heslin MJ, Leung DH, Lewis JJ, Brennan MF. Superficial extremity soft tissue sarcoma: an analysis of prognostic factors. Ann Surg Oncol 1998; 5: 41-47.
229. Enneking WF, McAuliffe JA. Adjunctive preoperative radiation therapy in treatment of soft tissue sarcomas: A preliminary report. Cancer Treust Symp 1985; 3: 37-42.
230. Barr LC, Stotter AT, A'Hern RP. Influence of local recurrence on survival: A controversy reviewed from the perspective of soft tissue sarcoma. Br J Surg 1991; 78: 648-650.
231. Collin C, Hajdu SI, Godbold J, Shiu MH, Hilaris BI, Brennan MF. Localized, operable soft tissue sarcoma of the lower extremity. Arch Surg 1986; 121: 1425-1433.
232. Lewis JJ, Leung D, Heslin M, Woodruff JM, Brennan MF. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol 1997; 15: 646-652.
233. Heslin MJ, Woodruff J, Brennan MF. Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: Implications for management. J Clin Oncol 1996; 14: 473-478.
234. Bell RS, O'Sullivan B, Liu FF, et al. The surgical margin in soft tissue sarcoma. J Bone Joint Surg 1989; 71A: 370-375.
235. Gaynor J, Tan C, Casper ES, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 1992; 10: 1317-1329.
236. Gadd MA, Casper ES, Woodruff JM, McCormack PM, Brennan MF. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg 1993; 218: 705-712.
237. Peabody TD, Monson D, Montag A, Schell MJ, Finn H, Simon MA. A comparison of the prognoses for deep and subcuta-neous sarcomas of the extremities. J Bone Joint Surg 1994; 76A: 1167-1173.
238. Brennan MF. The enigma of local recurrence. Ann Surg Oncol 1997; 4: 1-12.
239. Collin C, Hajdu SI, Godbold J, Friedrich C, Brennan MF. Localized, operable soft tissue sarcoma of the upper extremity: Presentation, management, and factors affecting local recurrence in 108 patients. Ann Surg 1987; 205: 331-339.
240. Gustafson P, Dreinhöfer KE, Rydholm A. Metastasis-free survival after local recurrence of soft-tissue sarcoma. J Bone Joint Surg 1993; 75B: 658-660.
241. Rööser B, Gustafson P, Rydholm A. Is there no influence of local control on the rate of metastases in high-grade soft tissue sarcoma? Cancer 1990; 65: 1727-1729.
242. Williard WC, Collin C, Casper ES, Hajdu SI, Brennan MF. The changing role of amputation for soft tissue sarcoma of the extremity in adults. Surg Gynecol Obstet 1992; 175: 389-396.
243. Levine EA, Holzmayer T, Bacus S, et al. Evaluation of newer prognostic markers for adult soft tissue sarcomas. J. Clin Oncol 1997; 15: 3249-3257.
244. Heslin MJ, Cordon-Cardo C, Lewis JJ, Woodruff JM, Brennan MF. Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high-grade, extremity soft tissue sarcoma. Cancer 1998; 38: 490-497.
245. Gustafson P, Ferno M, Akerman M, et al. Flow cytometric S-phase fraction in soft-tissue sarcoma: prognostic importance analysed in 160 patients. Br J Cancer 1997; 75: 94-100.
246. Taubert H, Meye A, Wurl P. Prognosis is correlated with P53 mutation type for soft tisue sarcoma patients. Cancer Res 1996; 56: 4134-4136.
247. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997; 40 [Suppl]: S3-S8.
248. Chan HSL, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein. Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990; 8: 689-704.
249. Toffoli G, Frustaci S, Tumiotto L, et al. Expression of MDR1 and GST-??? in human soft tissue sarcomas: relation to drug resistance and biologic aggressiveness. Ann Oncol 1992; 3: 63-69.
250. Stein U, Wunderlich V, Hansch W, Schmidt-Peter P. Expression of the MDR1 gene in bone ans soft tissue sarcomas of adult patients. Eur J Cancer 1993; 29A: 1979-1981.
251. Vergier B, Cany L, Bonnet F, Rober J, de Mascarel A, Coindre JM. Expression of MDR1/P-glycoprotein in human sarcomas. Br J Cancer 1993; 68: 1221-1226.
252. Stein U, Shoemaker RH, Schlag PM. MDR1 gene expression: Evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Eur J Cancer 1996; 32A: 86-92.
253. Oda Y, Schneiderstock R, Rys J, et al. Expression of multidrug resistance associated protein gene in human soft tissue sarcomas. J Cancer Res Clin Oncol 1996; 122: 161-165.
254. Slovak ML, Pelkey Ho J, Cole SPC, et al. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 1995; 55: 4214-4219.
255. List AF, Spier CS, Abbaszadegan M, et al. Non-P-glycoprotein (PGP) mediated multidrug resistance (MDR): identification of a noval drug resistance phenotype with prognostic relevance in acute myeloid leukemia (AML). Blood 1993; 82: 443a.
256. Izquierdo MA, van der Zee AG, Vermorken J, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230-1237.
257. Hochwald SN, Rose M, Brennan MF, Burt ME. Elevation of glutathione and related enzyme activities in high-grade and metastatic extremity soft tissue sarcoma. Ann Surg Oncol 1997; 4: 303-309.
258. Potter DA, Gleen J, Kinsella T, et al. Patterns of recurrence in patients with high-grade soft tissue sarcomas. J Clin Oncol 1985; 3: 353-366.
259. Mazanet R, Antman KH. Sarcomas of soft tissue and bone. Cancer 1991; 68: 463-473.
260. Talbert ML, Zagars GK, Sherman NE, Romsdahl MM. Conservative surgery and radiation therapy for soft tissue sarcoma of the wrist, hand, ankle and foot. Cancer 1990; 66: 2482-2491.
261. Fong Y, Coit D, Woodruff J, Brennan MF. Lymph node metas-tasis from soft tissue sarcoma in adults. Ann Surg 1993; 217: 72-77.
262. Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer 1987; 60: 1800-1808.
263. Weingrad DN, Rosenberg SA. Early lymphatic spread of osteogenic and soft-tissue sarcomas. Surgery 1978; 84: 231-240.
264. Geel AN van, Coevorden F van, Blankensteijn JD, et al. Surgical treatment of pulmonary metastases from soft tissue sarcomas: A retrospective study in The Netherlands. J Surg Oncol 1994; 56: 172-177.
265. Choong PFM, Pritchard DJ, Rock MG, Sim FH, Frassica FJ. Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients. Acta Orthop Scand 1995; 66: 561-568.
266. Casson AG, Putnam JB, Natarajan G, et al. Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer 1992; 69: 662-668.
267. Putnam JB, Roth JA, Wesley MN, Johnston MR, Rosenberg SA. Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 1984; 87: 260-268.
268. Jablons D, Steinberg SM, Roth J, Pittaluga S, Rosenberg SA, Pass HI. Metastasectomy for soft tissue sarcoma. Further evidence for efficacy and prognostic indicators. J Thorac Cardiovasc Surg 1989; 97: 695-705.
269. Verazin GT, Warneke JA, Driscoll DL, Karakousis C, Petrelli J, Takita H. Resection of lung metastases from soft tissue sarcoma. A multivariate analysis. Arch Surg 1992; 127: 1407-1411.
270. Geel AN van, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 1996; 77: 675-682.
271. Ueda T, Uchida A, Kodama K, et al. Aggressive pulmonary metastasectomy for soft tissue sarcomas. Cancer 1993; 72: 1919-1925.
272. Creagan ET, Fleming TR, Edmonson JH, Pairolero PC. Pulmonary resection for metastatic nonosteogenic sarcoma. Cancer 1979; 44: 1908-1912.
273. Lanza LA, Putnam JB, Benjamin RS, Roth JA. Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases. Ann Thorac Surg 1991; 51: 219-224.
274. Pastorino U, Valente M, Santoro A, et al. Results of salvage surgery for metastatic sarcomas. Ann Oncol 1990; 1: 269-273.
275. Roth JA, Putnam JB, Wesley MN, Rosenberg SA. Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Cancer 1985; 55: 1361-1366.
276. Rizzoni WE, Pass HI, Wesley MN, Rosenberg SA, Roth JA. Resection of recurrent pulmonary metastases in patients with soft tissue sarcomas. Arch Surg 1986; 121: 1248-1252.
277. Geel AN van, Hoekstra HJ, Coevorden F van, Meyer S, Bruggink ED, Blankensteijn JD. Repeated resection of recurrent pulmonary metastatic soft tissue sarcoma. Eur J Surg Oncol 1994; 20: 436-440.
278. Progebniak HW, Roth JA, Steinberg SM, Rosenberg SA, Passe HI. Reoperative pulmonary resection in patients with metastatic soft tissue sarcoma. Ann Thorac Surg 1991; 52: 197-203.
279. Stewart JR, Carey JA, Merrill WH, Frist WH, Hammon JWJ, Bender HWJ. Twenty years' experience with pulmonary metastasectomy. Am Surg 1992; 58: 100-103.
280. Johnston MR. Median sternotomy for resection of pulmonary metastases. J Thorac Cardiovasc Surg 1983; 85: 516-522.
281. Roth JA, Pass HI, Wesley MN, White D, Putnam JB, Seipp C. Comparison of median sternotomy and thoracotomy for resection of pulmonary metastases in patients with adult soft tissue sarcomas. Ann Thorac Surg 1986; 42: 134-138.
282. Elias AD. Salvage therapy for soft tissue sarcomas. Semin Oncol 1994; 21: 76-81.
283. Antman KH, Elias AD. Chemotherapy of advanced soft tissue sarcomas. Sem Surg Oncol 1988; 4: 53-58.
284. Borden EC, Amato D, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5: 840-850.
285. Elias A, Ryan L, Sulkus A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989; 7: 1208-1216.
286. Edmondson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-1275.
287. Antman KH, Ryan L, Elias A, Sherman D, Grier H. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989; 7: 126-131.
288. Bramwell V, Mouridsen H, Santoro G, et al. Cyclophosphamide vs ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcoma. Eur J Cancer 1987; 23: 311-321.
289. DeMetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Hematol Oncol Clin (Nth Am) 1995; 9: 765-785.
290. DeMetri GD. High dose ifosfamide in the treatment of sarcomas of soft tissue and bone. Semin Oncol 1996; 23: [Suppl 6]: 22-26.
291. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high dose ifosfamide (HDI) in advanced soft tissue sarcomas (STS). A multicenter phase II study of the EORTC soft tissue and bone sarcoma group. Proc Am Soc Clin Oncol 1998; 17:1992 (Abstr.).
292. Keohan ML, Taub RN. Chemotherapy for advanced sarcoma: therapeutic decisions and modalities. Semin Oncol 1997; 24: 572-579.
293. Steward WP, Verweij J, Somers R, et al. Granulocyte macrophage colony-stimulating factor allows safe escalation of dose intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993; 11: 15-21.
294. 1-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factors in advanced soft-tissue sarcomas: a pilot study. J Clin Oncol 1997; 15: 1418-1426.
295. Frustaci S, Gherlinzoni F, De Paoli A, et al. Preliminary results of an adjuvant randomized trial on high risk extremity soft tissue sarcomas (STS). The interim analysis. Proc Am Soc Clin Oncol 1997; 16: 1785 (Abstr.).
296. Budd GT, Metch B, Balcerzak SP, Fletcher WS, Baker LH, Mortimer JE. High-dose cisplatin for metastatic soft tissue sarcoma. Cancer 1990; 65: 866-869.
297. Goldstein D, Cheuvart B, Trump DL, et al. Phase II trial of carboplatin in soft-tissue sarcoma. Am J Clin Oncol 1990; 13: 420-423.
298. Quirt I, Eisenhauer E, Knowling M, et al A phase II study of trimetrexate in metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 1988; 7: 275 (Abstr. 1066).
299. Balcerzak SP, Benedetti J, Weiss GR, Natale RB. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas - A Southwest Oncology Group study. Cancer 1995; 76: 2248-2252.
300. van Hoesel QG, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994; 5: 539-542.
301. Kayl SB. Docetaxel (Taxotere) in the treatment of solid tumor other than breast and lung cancers. Semin Oncol 1995; 22: [Suppl 4]: 30-33.
302. Santoro A, Turez T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcoma: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tossue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537-1545.
303. Antmann KH, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276-1285.
304. Loehrer PJ, Sledge GW, Nicaise C, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: A multi-institutional Phase II trial. J Clin Oncol 1989; 7: 1655-1659.
305. Schutte J, Mouridsen HT, Steward W, et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1990; 26: 558-561.
306. Antman K, Baker L, Balcerzak S, Crowley J. An intergroup (SWOG & CALGB) Phase III randomized study of doxorubicin & dacarbazine with or without ifosfamide & mesna in advanced soft tissue and bone sarcomas. Proc Am Soc Clin Oncol 1990; 9: 311 (Abstr. 1203).
307. Bramwell V, Quirt I, Warr D, et al. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. J Natl Cancer Inst 1989; 81: 1496-1499.
308. Kirchner HH, Schmoll HJ, Poliwoda H. Treatment of advanced soft-tissue sarcomas with ifosfamide (IFF) and adriamycin (ADM). J Cancer Res Clin Oncol 1986; 111 [Suppl]: S30.
309. Hartlapp JH, Munch HJ, Illiger J, Wolter H, Jensen JC. Alternatives to CYVADIC combination therapy of soft tissue sarcomas. Cancer Chemother Pharmacol 1986; 18 [Suppl 2]: S20-22.
310. Yap BS, Baker LH, Sinkovics JG, et al. Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Res 1980; 64: 93-98.
311. Bramwell VHC. Chemotherapy for metastatic soft tissue sarcoma - another full circle? Br J Cancer 1991; 64: 7-9.
312. Baker LH, Frank J, Fine G, et al. Combination chemotherapy using adriamycin, DTIC, Cyclophosphamide and actinomycin D for advanced soft tissue sarcoma: a randomized comparative trial. J Clin Oncol 1987; 5: 851-861.
313. Sæter G. Chemotherapy for adult soft tissue sarcoma. Does it work? Acta Orthop Scand 1997; 68 [Suppl 273]: 139-144.
314. Sæter G, Talle K, Soldheim Ø. Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. Cancer Chemother Pharmacol 1995; 36: 172-175.
315. Schmidt RA, Conrad III, EU, Collins C, Rabinovitch P, Finney A. Measurement and prediction of the short-term response of soft-tissue sarcomas to chemotherapy. Cancer 1993; 72: 2593-2601.
316. Van Haelst Pisani CM, Buckner JC, Reiman HM, Schaid DJ, Edmonson JH, Hahn RG. Does histologic grade in soft tissue sarcoma influence response rate to systemic chemotherapy? Cancer 1991; 68: 2354-2358.
317. Bray J-Y, van Glabbeke M, Nielsen OS, et al Five-year survivors in patients with advanced soft tissue sarcoma treated with doxorubicin: a study on 1742 patients. Proc Am Soc Clin Oncol 1998; 17:1973 (abstr.).
318. Gustafson P, Dreinhofer KE, Rydholm A. Soft tissue sarcoma should be treated at a tumor center: a comparison of quality of surgery in 375 patients. Acta Orthop Scand 1994; 65: 47-50.
319. Goodlad JR, Fletcher CDM, Smith MA. Surgical resection of primary soft-tissue sarcoma. Incidence of residual tumour in 95 patients needing re-excision after local resection. J Bone Joint Surg 1996; 78B: 658-661.